Head-to-Head: Zanubrutinib vs Ibrutinib in Waldenström Macroglobulinemia
Zanubrutinib demonstrated statistically significant and clinically meaningful advantages in safety and tolerability in patients with WM compared with ibrutinib.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
